WuXi PharmaTech Plans to List Subsidiary on China's Third Board

WuXi PharmaTech, China's largest CRO/CMO, has filed to list its chemical manufacturing subsidiary, SynTheAll Pharmaceutical Co. Ltd., on China's Third Board, a two-year old electronic OTC exchange. Although it has submitted a listing application, WuXi said it may not conduct an IPO for STA immediately after approval. WuXi further explained that its chemical CMO subsidiary requires greater capital investment than the other parts of its CRO/CMO business, though the company was careful to point out that STA does not include WuXi's biologic drug manufacturing operations. More details.... Stock Symbol: (NYSE: WX) Share this with colleagues: // //